BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Sha M, Chen C, Shen C, Jeong S, Sun H, Xu N, Hang H, Cao J, Tong Y. Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study. Front Oncol 2022;12:971532. [DOI: 10.3389/fonc.2022.971532] [Reference Citation Analysis]
2 Ibrahim UH, Devnarain N, Mohammed M, Omolo CA, Gafar MA, Salih M, Pant A, Shunmugam L, Mocktar C, Khan R, Oh JK, Govender T. Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer. Int J Biol Macromol 2022;222:546-61. [PMID: 36150574 DOI: 10.1016/j.ijbiomac.2022.09.173] [Reference Citation Analysis]
3 Nadalin S, Peters M, Königsrainer A. Operative Therapiestrategien bei primären Lebertumoren, hepatozellulären und Cholangio- inkl. Gallenblasenkarzinomen. Allgemein- und Viszeralchirurgie up2date 2022;16:313-331. [DOI: 10.1055/a-1739-8909] [Reference Citation Analysis]
4 Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Current Opinion in Organ Transplantation 2022;27:312-319. [DOI: 10.1097/mot.0000000000000997] [Reference Citation Analysis]
5 Zhang Z, Li C, Liao W, Huang Y, Wang Z. A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers (Basel) 2022;14:3619. [PMID: 35892878 DOI: 10.3390/cancers14153619] [Reference Citation Analysis]
6 Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends 2022. [PMID: 35732434 DOI: 10.5582/bst.2022.01245] [Reference Citation Analysis]
7 He C, Ge N, Wang X, Li H, Chen S, Yang Y. Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization. Front Oncol 2022;12:923566. [DOI: 10.3389/fonc.2022.923566] [Reference Citation Analysis]
8 Yu JI, Kang W, Yoo GS, Goh MJ, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Hong JY, Lim HY, Park B, Park HC. Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. Front Oncol 2022;12:888755. [PMID: 35646674 DOI: 10.3389/fonc.2022.888755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, Hou J. A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. Front Oncol 2021;11:783194. [PMID: 34869036 DOI: 10.3389/fonc.2021.783194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]